Drugmakers appeal limited insurance benefit for dementia drug choline alfoscerate

 9 July 2020 - Sixty-six manufacturers of choline alfoscerate, a dementia drug, filed an appeal to the Health Insurance Review ...

Read more →

'Xolair’s reimbursement will change treatment paradigm for asthma patients'

9 July 2020 - Novartis Korea will be able to strengthen its position in the severe allergic asthma market with ...

Read more →

EMA and Korean Ministry of Food and Drug Safety to share confidential COVID-19 information

30 June 2020 - EMA and the Ministry of Food and Drug Safety of the Republic of Korea have signed ...

Read more →

‘Government should lower prices of generic drugs’

29 June 2020 - “Our policy should aim at reaching the OECD average of general drug use, additionally cut generic ...

Read more →

Dementia drug choline alfoscerate to get limited insurance benefit

12 June 2020 - The government has allowed choline alfoscerate, a dementia drug, to continue to receive the national health ...

Read more →

Orphan drug reimbursements create tough situation for South Korean public budget

12 June 2020 - A data analysis of real-world data found that the rise of orphan drugs in the Republic of ...

Read more →

'Imfinzi changed treatment paradigm for non-resectable non-small cell lung cancer'

10 June 2020 - The treatment has also become the first immunotherapy launched in Korea to receive health insurance benefits as ...

Read more →

South Korea approves emergency use of Gilead's anti-viral drug to treat COVID-19

3 June 2020 - South Korea said on Wednesday it has approved the emergency use of Gilead Sciences’ remdesivir to ...

Read more →

CDK 4/6 inhibitor market to heat up on insurance benefits

2 June 2020 - Despite such high unmet medical needs, the drug has long been out of reach for patients ...

Read more →

Government to re-evaluate dementia drug choline alfoscerate

18 May 2020 - The Ministry of Health and Welfare said it would reassess whether choline alfoscerate, a dementia treatment, ...

Read more →

Cancer patients demand Ono, BMS, MSD share immunotherapy cost

15 May 2020 - Immunotherapies Optivo, marketed by Ono Pharma Korea and BMS Korea, and Keytruda by MSD Korea, have ...

Read more →

Review of cancer drug benefits delayed amid social distancing

8 April 2020 - The government has postponed the health authorities’ meeting for a review of anticancer drugs’ benefits initially ...

Read more →

Price negotiations begin for breast cancer combo drugs

25 March 2020 - Drug makers and the government will start talks this week to negotiate prices of breast cancer ...

Read more →

Gastric cancer drug Liporaxel nears getting insurance benefit

6 March 2020 - Daehwa Pharmaceutical’s Liporaxel (paclitaxel), a treatment for advanced, metastatic and local recurrent gastric cancer, has neared ...

Read more →

Regulator OKs Pfizer's Vizimpro as first-line treatment of mutated lung cancer

20 February 2020 - Pfizer Korea said Thursday that the Ministry of Food and Drug Safety has approved Vizimpro (dacomitinib) ...

Read more →